SCHEMBL19862620

SCHEMBL19862620

Cc1ccc(C2CNC(=O)[C@H]2C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.58
PDE4B Q07343 1/20 0.58
PDE4C Q08493 1/20 0.58
PDE4D Q08499 1/20 0.58
SLC6A3 Q01959 10/20 0.46
SLC6A2 P23975 10/20 0.46
SLC6A4 P31645 3/20 0.46
MAPT P10636 1/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
FFAR1 O14842 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
NAAA Q02083 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18590455 1.00 PDE4A (0.58) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL18590471 1.00 PDE4A (0.58) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL18590577 1.00 PDE4A (0.58) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL13473787 0.83 PDE4A (0.55) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL22559997 0.83 PDE4A (0.55) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL13473789 0.83 PDE4A (0.55) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL20408748 0.82 MAPT (0.43) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL19559470 0.81 PDE4A (0.66) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL11092947 0.80 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DSLC6A3
SCHEMBL18590483 0.78 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10029983-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2018-07-24 US disclosed
US-20180044290-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KYORIN SEIYAKU KK (JP) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10029983-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 PDE4A 919/4885PDE4B 1256/4885PDE4C 1451/4885
US-20180044290-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF FPR1, FPR2, FPR3 PDE4A 919/4885PDE4B 1256/4885PDE4C 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.